Tabersonine enhances cisplatin sensitivity by modulating Aurora kinase A and suppressing epithelial–mesenchymal transition in triple-negative breast cancer

References

• Ashrafizadeh M, Zarrabi A, Hushmandi K, Kalantari M, Mohammadinejad R, Javaheri T, Sethi G. 2020. Association of the epithelial-mesenchymal transition (EMT) with cisplatin resistance. Int J Mol Sci. 21(11):4002. doi: 10.3390/ijms21114002.
   PubMed Web of Science ®Google Scholar
• Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, Wilsher NE, Martins V, Reynisson J, Atrash B, et al. 2010. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem. 53(14):5213–5228. doi: 10.1021/jm100262j.
   PubMed Web of Science ®Google Scholar
• Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, Bilani N, Jaafar R, Nahleh Z. 2022. Triple negative breast cancer: updates on classification and treatment in 2021. Cancers (Basel). 14(5):1253. doi: 10.3390/cancers14051253.
   PubMed Web of Science ®Google Scholar
• Cánovas B, Igea A, Sartori AA, Gomis RR, Paull TT, Isoda M, Pérez-Montoyo H, Serra V, González-Suárez E, Stracker TH, et al. 2018. Targeting p38alpha increases DNA damage, chromosome instability, and the anti-tumoral response to taxanes in breast cancer cells. Cancer Cell. 33(6):1094–1110 e1098. doi: 10.1016/j.ccell.2018.04.010.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne U, et al. 2022. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 25:18–27. doi: 10.1016/j.neo.2022.01.001.
   PubMed Web of Science ®Google Scholar
• Chen C, Song G, Xiang J, Zhang H, Zhao S, Zhan Y. 2017. AURKA promotes cancer metastasis by regulating epithelial-mesenchymal transition and cancer stem cell properties in hepatocellular carcinoma. Biochem Biophys Res Commun. 486(2):514–520. doi: 10.1016/j.bbrc.2017.03.075.
   PubMed Web of Science ®Google Scholar
• Chen K, Xu J, Tong YL, Yan JF, Pan Y, Wang WJ, Zheng L, Zheng XX, Hu C, Hu X, et al. 2023. Rab31 promotes metastasis and cisplatin resistance in stomach adenocarcinoma through Twist1-mediated EMT. Cell Death Dis. 14(2):115. doi: 10.1038/s41419-023-05596-4.
   PubMed Web of Science ®Google Scholar
• Chen SH, Chang JY. 2019. New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment. Int J Mol Sci. 20(17):4136. doi: 10.3390/ijms20174136.
   PubMed Web of Science ®Google Scholar
• Chen X, Yan Y, Liu W, Liu Y, Thakur A, Liang Q, Xu Z. 2023. Targeting RAS guanyl releasing protein 1 promotes T lymphocytes infiltrations and improves anti-programmed death receptor ligand 1 therapy response of triple-negative breast cancer. Clin Transl Med. 13(7):e1335.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lin W, Chen P, Ye B, Luo W, Wang X, Huang W, Wu G, Liang G. 2023. Tabersonine alleviates obesity-induced cardiomyopathy by binding to transforming growth factor activated kinase 1 (TAK1) and inhibiting TAK1-mediated inflammation. Phytother Res. 37(3):860–871. doi: 10.1002/ptr.7666.
   PubMed Web of Science ®Google Scholar
• Dawei H, Honggang D, Qian W. 2018. AURKA contributes to the progression of oral squamous cell carcinoma (OSCC) through modulating epithelial-to-mesenchymal transition (EMT) and apoptosis via the regulation of ROS. Biochem Biophys Res Commun. 507(1–4):83–90. doi: 10.1016/j.bbrc.2018.10.170.
   PubMed Web of Science ®Google Scholar
• Deepak KGK, Vempati R, Nagaraju GP, Dasari VR, S N, Rao DN, Malla RR. 2020. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 153:104683. doi: 10.1016/j.phrs.2020.104683.
   PubMed Web of Science ®Google Scholar
• Du R, Huang C, Liu K, Li X, Dong Z. 2021. Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer. 20(1):15. doi: 10.1186/s12943-020-01305-3.
   PubMed Web of Science ®Google Scholar
• Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P, et al. 2006. 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem. 49(24):7247–7251. doi: 10.1021/jm060897w.
   PubMed Web of Science ®Google Scholar
• Ghosh S. 2019. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 88:102925. doi: 10.1016/j.bioorg.2019.102925.
   PubMed Web of Science ®Google Scholar
• Gyorffy B. 2021. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 19:4101–4109.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Arani HZ, Orouei S, Fallah S, Ghorbani A, Khaledabadi M, Kakavand A, Tavakolpournegari A, Saebfar H, Heidari H, et al. 2022. EMT mechanism in breast cancer metastasis and drug resistance: revisiting molecular interactions and biological functions. Biomed Pharmacother. 155:113774. doi: 10.1016/j.biopha.2022.113774.
   PubMed Web of Science ®Google Scholar
• Huang M, Liu C, Shao Y, Zhou S, Hu G, Yin S, Pu W, Yu H. 2022. Anti-tumor pharmacology of natural products targeting mitosis. Cancer Biol Med. 19(6):774–801. doi: 10.20892/j.issn.2095-3941.2022.0006.
   PubMed Web of Science ®Google Scholar
• Jalalirad M, Haddad TC, Salisbury JL, Radisky D, Zhang M, Schroeder M, Tuma A, Leof E, Carter JM, Degnim AC, et al. 2021. Aurora-A kinase oncogenic signaling mediates TGF-beta-induced triple-negative breast cancer plasticity and chemoresistance. Oncogene. 40(14):2509–2523. doi: 10.1038/s41388-021-01711-x.
   PubMed Web of Science ®Google Scholar
• Ke CS, Liu HS, Yen CH, Huang GC, Cheng HC, Huang CY, Su CL. 2014. Curcumin-induced Aurora-A suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs. J Nutr Biochem. 25(5):526–539. doi: 10.1016/j.jnutbio.2014.01.003.
   PubMed Web of Science ®Google Scholar
• Lemos Cruz P, Kulagina N, Guirimand G, De Craene JO, Besseau S, Lanoue A, Oudin A, Giglioli-Guivarc’h N, Papon N, Clastre M, et al. 2021. Optimization of tabersonine methoxylation to increase vindoline precursor synthesis in yeast cell factories. Molecules. 26(12):3596. doi: 10.3390/molecules26123596.
   PubMed Web of Science ®Google Scholar
• Lin C, Cui J, Peng Z, Qian K, Wu R, Cheng Y, Yin W. 2022. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis. Eur J Med Res. 27(1):201. doi: 10.1186/s40001-022-00839-0.
   PubMed Web of Science ®Google Scholar
• Liu T, Huang Y, Jiang L, Dong C, Gou Y, Lian J. 2021. Efficient production of vindoline from tabersonine by metabolically engineered Saccharomyces cerevisiae. Commun Biol. 4(1):1089. doi: 10.1038/s42003-021-02617-w.
   PubMed Web of Science ®Google Scholar
• Liu X, Li Z, Song Y, Wang R, Han L, Wang Q, Jiang K, Kang C, Zhang Q. 2016. AURKA induces EMT by regulating histone modification through Wnt/beta-catenin and PI3K/Akt signaling pathway in gastric cancer. Oncotarget. 7(22):33152–33164. doi: 10.18632/oncotarget.8888.
   PubMedGoogle Scholar
• Liu X, Ouyang S, Yu B, Liu Y, Huang K, Gong J, Zheng S, Li Z, Li H, Jiang H. 2010. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res. 38:W609–614. doi: 10.1093/nar/gkq300.
   PubMed Web of Science ®Google Scholar
• Liu X, Zou H, Zhao Y, Chen H, Liu T, Wu Z, Yang C, Li Q, Li Y. 2020. Tanshinone inhibits NSCLC by downregulating AURKA through Let-7a-5p. Front Genet. 11:838. doi: 10.3389/fgene.2020.00838.
   PubMed Web of Science ®Google Scholar
• Luo J, Yao JF, Deng XF, Zheng XD, Jia M, Wang YQ, Huang Y, Zhu JH. 2018. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin alphavbeta3 and activating FAK/PI3K/AKT signaling. J Exp Clin Cancer Res. 37(1):23. doi: 10.1186/s13046-018-0694-6.
   PubMedGoogle Scholar
• Nedeljkovic M, Damjanovic A. 2019. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells. 8:957.
   PubMed Web of Science ®Google Scholar
• Qian C, Wang J, Lin W, Chen Y, Yang J, Liu M, Sun X, Wu H, Zhang M, Wang Y, et al. 2023. Tabersonine attenuates obesity-induced renal injury via inhibiting NF-kappaB-mediated inflammation. Phytother Res. 37(6):2353–2363. doi: 10.1002/ptr.7756.
   PubMed Web of Science ®Google Scholar
• Serrano-Gomez SJ, Maziveyi M, Alahari SK. 2016. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 15(1):18. doi: 10.1186/s12943-016-0502-x.
   PubMed Web of Science ®Google Scholar
• Shi S, Song L, Liu Y, He Y. 2020. Activation of CREB protein with tabersonine attenuates STAT3 during atherosclerosis in apolipoprotein E-deficient mice. Dose Response. 18(1):1559325820912067. doi: 10.1177/1559325820912067.
   Web of Science ®Google Scholar
• Sun X, Gan L, Li N, Sun S, Li N. 2020. Tabersonine ameliorates osteoblast apoptosis in rats with dexamethasone-induced osteoporosis by regulating the Nrf2/ROS/Bax signalling pathway. AMB Express. 10(1):165. doi: 10.1186/s13568-020-01098-0.
   PubMed Web of Science ®Google Scholar
• Wang B, Sun T, Zhao Y, Wang S, Zhang J, Wang Z, Teng YE, Cai L, Yan M, Wang X, et al. 2022. A randomized phase 3 trial of gemcitabine or nab-paclitaxel combined with cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer. Nat Commun. 13(1):4025. doi: 10.1038/s41467-022-31704-7.
   PubMed Web of Science ®Google Scholar
• Wang L, Arras J, Katsha A, Hamdan S, Belkhiri A, Ecsedy J, El-Rifai W. 2017. Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib. Mol Oncol. 11(8):981–995. doi: 10.1002/1878-0261.12066.
   PubMed Web of Science ®Google Scholar
• Wu J, Powell F, Larsen NA, Lai Z, Byth KF, Read J, Gu RF, Roth M, Toader D, Saeh JC, et al. 2013. Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-oxozeaenol. ACS Chem Biol. 8(3):643–650. doi: 10.1021/cb3005897.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang W, Font-Burgada J, Palmer T, Hamil AS, Biswas SK, Poidinger M, Borcherding N, Xie Q, Ellies LG, et al. 2014. Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade. Proc Natl Acad Sci USA. 111(38):13870–13875. doi: 10.1073/pnas.1414358111.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhang Y, Dai H, Han B. 2022. Epithelial-mesenchymal transition-mediated tumor therapeutic resistance. Molecules. 27(15):4750. doi: 10.3390/molecules27154750.
   PubMed Web of Science ®Google Scholar
• Yan H, Luo B, Wu X, Guan F, Yu X, Zhao L, Ke X, Wu J, Yuan J. 2021. Cisplatin induces pyroptosis via activation of MEG3/NLRP3/caspase-1/GSDMD Pathway in triple-negative breast cancer. Int J Biol Sci. 17(10):2606–2621. doi: 10.7150/ijbs.60292.
   PubMed Web of Science ®Google Scholar
• Yin L, Duan JJ, Bian XW, Yu SC. 2020. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22(1):61. doi: 10.1186/s13058-020-01296-5.
   PubMed Web of Science ®Google Scholar
• Yu Z, Cao W, Ren Y, Zhang Q, Liu J. 2020. ATPase copper transporter A, negatively regulated by miR-148a-3p, contributes to cisplatin resistance in breast cancer cells. Clin Transl Med. 10(1):57–73. doi: 10.1002/ctm2.19.
   PubMed Web of Science ®Google Scholar
• Zhang D, Li X, Hu Y, Jiang H, Wu Y, Ding Y, Yu K, He H, Xu J, Sun L, et al. 2018. Tabersonine attenuates lipopolysaccharide-induced acute lung injury via suppressing TRAF6 ubiquitination. Biochem Pharmacol. 154:183–192. doi: 10.1016/j.bcp.2018.05.004.
   PubMed Web of Science ®Google Scholar